By Fineline Cube 
CanSino Biologics (HKG: 6185) announced that it reached a cooperation intent with its Pakistani partner AGP Limited on the 13‑Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13i). The two parties will further explore future development opportunities for this product in Pakistan.
Deal Overview
| Item | Detail |
|---|---|
| Companies | CanSino Biologics (HKG: 6185) / AGP Limited (Pakistan) |
| Agreement Type | Cooperation intent |
| Product | 13‑Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13i) |
| Geographic Scope | Pakistan |
| Announcement Date | 2 Jul 2026 |
| Next Steps | Explore future development opportunities for PCV13i in Pakistan |
Product Profile
- Vaccine: PCV13i, a 13‑valent pneumococcal polysaccharide conjugate vaccine.
- Target Disease: Invasive pneumococcal disease — a leading cause of childhood pneumonia and meningitis in emerging markets.
- Market Positioning: Conjugate pneumococcal vaccines are among the most widely demanded childhood immunizations globally, with supply and affordability remaining key challenges in South Asia.
Track Record With Pakistan
- March 2021: The first batches of CanSino’s finished‑product COVID‑19 vaccine arrived in Pakistan.
- June 2021: Pakistan completed local fill‑and‑finish production of CanSino’s COVID‑19 vaccine — an early milestone in building the country’s local vaccine manufacturing capacity.
- Ongoing Partnership: The PCV13i cooperation intent builds on this established vaccine collaboration between CanSino Biologics and Pakistan.
Market Impact & Outlook
- Pakistan’s Health Priorities: Pakistan has long prioritized improving vaccine accessibility and building local healthcare industry capacity, aligning with CanSino’s localization‑friendly partnership model.
- South Asia Footprint: The PCV13i cooperation intent will further expand CanSino Biologics’ footprint in the South Asian market, extending its portfolio beyond viral vaccines into routine pediatric immunization.
- Strategic Continuity: Leveraging an existing partner with fill‑and‑finish experience lowers execution risk and provides a potential platform for broader vaccine supply in the region.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding product development and partnership intentions for PCV13i. Actual results may differ due to risks including regulatory approvals, definitive agreement terms, and market conditions.-Fineline Info & Tech